This study tested the effect of the HMG-CoA reductase inhibitor, lovastatin, on early-stage carotid atherosclerosis (as detected by B-mode ultrasonography) in 919 asymptomatic men and women, 40-79 years of age with moderately elevated LDL cholesterol.
- Warfarin (Coumadin®)Drug
Intervention Desc: Anticoagulant (Vitamin K antagonist)
- Lovastatin (Mevacor)Drug
Other Names: Mevacor Intervention Desc: 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor; lowers cholesterol
Double-blind, placebo-controlled, factorially designed study of 919 patients.
Participants received lovastatin (20-40 mg/day) or lovastatin-placebo and warfarin (1 mg/day), or warfarin-placebo over a 3-year period.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Progression of the mean maximum intimal-medial thickness (IMT) over 12 walls of both carotid arteries.|